Increased antimicrobial susceptibility rates for Pseudomonas aeruginosa bloodstream isolates across the Veterans Affairs Healthcare System

Diagnostic Microbiology and Infectious Disease

Volumn 82, Issue 3, 2015, Pages 215-221

  Gentry, Chris A ^a   Williams, Riley J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Pseudomonas aeruginosa; Surveillance; Susceptibility

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; GEOGRAPHIC DISTRIBUTION; HOSPITAL INFECTION; INCIDENCE; MIC50; MIC90; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PUBLIC HOSPITAL; UNITED STATES; ANTIBIOTIC RESISTANCE; BACTEREMIA; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; HEALTH CARE DELIVERY; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; VETERAN;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DELIVERY OF HEALTH CARE; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; HUMANS; INCIDENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; UNITED STATES; VETERANS;

EID: 84939168057     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.03.020     Document Type: Article

References (23)

1. Fagan R.P., Edwards J.R., Park B.J., Fridkin S.K., Magill S.S. Incidence trends in pathogen-specific central line-associated bloodstream infections in US intensive care units, 1990-2010. Infect Control Hosp Epidemiol 2013, 34(9):893-899.
2. Jain R., Kralovic S.M., Evans M.E., Ambrose M., Simbartl L.A., Obrosky S., et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med 2011, 364(15):1419-1430. 10.1056/NEJMoa1007474.
3. Jones R.N., Stilwell M.G., Rhomberg P.R., Sader H.S. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). Diagn Microbiol Infect Dis 2009, 65(3):331-334. 10.1016/j.diagmicrobio.2009.06.022.
4. Kallen A.J., Hidron A.I., Patel J., Srinivasan A. Multidrug resistance among Gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 2010, 31(5):528-531.
5. Kang C.I., Kim S.H., Kim H.B., Park S.W., Choe Y.J., Oh M.D., et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003, 37(6):745-751.
6. Landelle C., Pagani L., Harbarth S. Is patient isolation the single most important measure to prevent the spread of multidrug-resistant pathogens?. Virulence 2013, 4(2):163-171. 10.4161/viru.22641.
7. Lodise T.P., Patel N., Kwa A., Graves J., Furuno J.P., Graffunder E., et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007, 51(10):3510-3515.
8. Master R.N., Clark T.B., Karlowsky J.A., Ramirez J., Bordon J.M. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009. Int J Antimicrob Agents 2011, 38:291-295.
9. Micek S.T., Lloyd A.E., Ritchie D.J., Reichley R.M., Fraser V.J., Kollef M.H. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49(4):1306-1311.
10. Morrow B.J., Pillar C.M., Deane J., Sahm D.F., Lynch A.S., Flamm R.K., et al. Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. Diagn Microbiol Infect Dis 2013, 75(4):412-416. 10.1016/j.diagmicrobio.2012.12.012.
11. Obritsch M.D., Fish D.N., MacLaren R., Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004, 48(12):4606-4610.
12. Osih R.B., McGregor J.C., Rich S.E., Moore A.C., Furuno J.P., Perencevich E.N., et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2007, 51(3):839-844.
13. Rhomberg P.R., Jones R.N. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009, 65(4):414-426. 10.1016/j.diagmicrobio.2009.08.020.
14. Sievert D.M., Ricks P., Edwards J.R., Schneider A., Patel J., Srinivasan A., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol 2013, 34(1):1-14. 10.1086/668770.
15. Szabo C.R. 2005 Facility Complexity Model 2005, Veterans Healthcare Administration National Leadership Board Human Resources Committee, Washington, DC.
16. Tam V.H., Chang K.T., Abdelraouf K., Brioso C.G., Ameka M., McCaskey L.A., et al. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010, 54(3):1160-1164.
17. United States Department of Veterans Affairs National Center for Veterans Analysis and Statistics Quick facts [Published May, 2014. Accessed on July 7, 2014]. http://www.va.gov/vetdata/Quick_Facts.asp.
18. VHA Memorandum Acting Assistant Deputy Under Secretary for Health for Operations and Management for Clinical Operations (10NC). Implementation of guideline for prevention of Clostridium difficile infection (CDI) in Veterans Health Administration (VHA) acute-care facilities (VAIQ # 7210267) 2012, [Washington, D.C.].
19. Veterans Healthcare Administration VHA Directive 1031 Antimicrobial Stewardship Programs (ASP). Veterans Healthcare Administration [Published January 22, 2014. Accessed July 7, 2014]. http://vaww1.va.gov/vhapublications/ViewPublication.asp?pub_ID=2964.
20. Veterans Healthcare Administration VHA Directive 2007-002, Methicillin Resistant Staphylococcus aureus (MRSA) Initiative [Published January 12, 2007. Accessed July 7, 201]. http://www.neverevents.org/infections/downloads/VHA-MRSA-Directive-2007-002.pdf.
21. Vidal F., Mensa J., Almela M., Martinez J.A., Marco F., Casals C., et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996, 156(18):2121-2126.
22. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309-317.
23. World Health Organization (WHO) WHO Global Strategy for Containment of Antimicrobial Resistance Published May, 2001, [Accessed on May 15, 2014]. http://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf?ua=1.